Unicycive Therapeutics, Inc. (UNCY) Stock Score, Valuation & Financial Research

Unicycive Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for UNCY

Unicycive Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 4.67. These figures are a research snapshot, not a buy or sell recommendation.

What Unicycive Therapeutics, Inc. does

Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Unicycive Therapeutics is a clinical-stage biotechnology company that operates by licensing proprietary technologies and drug candidates. The company focuses on the development, regulatory approval, and eventual commercialization of these products in global markets, primarily targeting kidney diseases.

Products and services

  • The company's pipeline includes Oxylanthanum Carbonate (OLC), a novel phosphate-binding agent for patients with chronic kidney disease, and UNI-494, a drug candidate for acute kidney injury.

Brands and product families

  • Oxylanthanum Carbonate — Lead investigational phosphate-binding agent for chronic kidney disease. Source
  • UNI-494 — Investigational drug candidate for acute kidney injury. Source

Customer types

Patients with chronic kidney disease; Patients with acute kidney injury.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical and commercial drug supplies; the specific supplier companies are unnamed. Source

Business strengths to evaluate

  • Utilization of the 505(b)(2) regulatory pathway for drug approval Source

Business risks and research considerations

  • Dependence on third-party manufacturers for drug supply Source
  • Uncertainty of regulatory approval for product candidates Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

UNCY financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 4.67
Market capitalization:
124.56M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -35.22M
Free cash flow:
USD -31.34M
Cash:
USD 44.19M
Total debt:
USD 671K
EPS:
USD -1.67

What stands out

  • Free cash flow is USD -31.34M, negative for the stored period.
  • The balance sheet shows USD 44.19M of cash versus USD 671K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 43.51M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for UNCY

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can UNCY fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is UNCY likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for UNCY to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of UNCY's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research UNCY

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.